Stock comparison
Harmony Biosciences Holdings
Dr. Reddy's Laboratories Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
RDY
Dr. Reddy's Laboratories Limited
Market cap
$11.32B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | RDY | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 57C | HRMY |
| Benjamin Graham | 60C | 72B | RDY |
| Philip Fisher | 75B | 61C | HRMY |
| Peter Lynch | 62C | 55C | HRMY |
| Joel Greenblatt | 28F | 46D | RDY |
| Charlie Munger | 62C | 49D | HRMY |
| Terry Smith | 67B | 45D | HRMY |
Side-by-side metrics
| Metric | HRMY | RDY |
|---|---|---|
| Market cap | $1.75B | $11.32B |
| P/E (TTM) | 11.8x | 26.0x |
| EV/EBIT | 6.4x | 24.0x |
| ROIC (TTM) | 12.5% | 8.07% |
| Gross margin | 76.55% | 52.77% |
| Net margin | 16.2% | 12.76% |
| Revenue CAGR 5y | 29.85% | 13.31% |
| EPS CAGR 5y | 46.45% | 17.36% |
| Debt / Equity | 0.2x | 0.2x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 24.0x+73%
- EPS CAGR 5y46.45%vs 17.36%+63%
- Revenue CAGR 5y29.85%vs 13.31%+55%
- P/E (TTM)11.8xvs 26.0x+54%
RDY leads on
- Dividend yield0.6%vs 0.0%+100%
- Market cap$11.32Bvs $1.75B+85%
- Debt / Equity0.2xvs 0.2x+10%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.